ABIVAX Stock: Shares Down 8.36% at Close
Abivax experienced a significant correction at the close of trading on Monday, with shares ending the day below 83.30 euros. This decline is in stark contrast to the biotech's long-term upward trajectory, which continues to show astonishing gains over the past twelve months. The low trading volume raises questions about the stability of the technical rebound that began earlier in the week.
Significant Drop in Abivax Shares
Abivax shares saw a sharp decline on Monday, November 3, dropping 8.36% from the previous close of 90.90 euros. At 83.30 euros, the price is approaching the major support threshold around 69.40 euros, marking the extent of the correction since the intraday peak. Trading volume remained low, with only 0.22% of the company's capital changing hands, indicating limited commercial activity during this session. This setup suggests volatility without conviction among market participants. Comparatively, the CAC 40 retreated by only 0.14% over the same period, highlighting the idiosyncratic weakness of the stock relative to the overall Parisian market. However, longer-term performance remains spectacular: over seven days, Abivax is up 5.18%, while quarterly performance reached 36.11%. The annual tally remains impressive with an appreciation of 776.8%, far exceeding the CAC 40's twelve-month progress, which is limited to 9.46%.
Monday's Decline Amid Capitalistic Adjustments
Monday's decline occurred in a context of capitalistic adjustments among major shareholders. Sofinnova Partners crossed below the 10% voting rights threshold on October 29, following a share sale both off and on the market. The venture capital fund now holds 4.33 million shares, representing 9.42% of the biotech's voting rights. Earlier, at the beginning of October, Abivax presented the latest results of its eight-week ABTECT trial, along with updated tolerability data. The group also reported positive data concerning obefazimodin, its phase 3 candidate, which had been well received by the market when announced. Analyst consensus points to a target price of 97.87 euros in three months, suggesting a potential rebound of about 17% from current levels. Abivax has been included in the CAC Mid 60 and SBF 120 indices since September following an annual review by Euronext Paris.
Technical Indicators Show Mixed Signals at Session End
Technically, the stock shows mixed signals at the end of the session. The Relative Strength Index (RSI) is positioned at 67, a level that places the stock in overbought territory according to conventional standards, while the Stochastic Oscillator sends a sell signal. The MACD, a momentum indicator, remains positive at 3.45 with a signal line at 2.51, displaying a histogram of 0.95. The 50-day moving average is established at 74.71 euros, well below the current price. The 200-day moving average remains much lower at 29.53 euros. The stock thus moves well above its two major moving averages, confirming a structurally bullish orientation. The Bollinger Bands define a range between 72.31 euros and 89.09 euros, with the current price retreating from the upper band. The one-month volatility reaches 13.81%, reflecting the characteristic oscillations of biotechnology sector stocks.
